Drugs / LuminoMark
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03743259 | May 2018 → Jan 2019 | breast disorder | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04606329 | Jul 2020 → Jan 2021 | breast disorder | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07380867 | Dec 2025 → Dec 2026 expected | colorectal cancer | Seoul St. Mary's Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LuminoMark | “The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMark™) for localization in patients with non-palpable breast lesions: a multi-center open-label...” PMID 33726718 ↗ Mar 2021 |
| Known as | LuminoMark inj.(Conc. for fluorescence) 0.1mL | “LuminoMark inj.(Conc. for fluorescence) 0.1mL” NCT03743259 ↗ |
| Modality | Diagnostic / imaging agent | “LuminoMark inj. (Conc. for fluorescence) localization” NCT04606329 ↗ |
| Route | Other | “Through endoscopy, Luminomarker injection on submucosal layer.” NCT07380867 ↗ |